Cogent Biosciences, Inc. Available-for-sale Securities, Amortized Cost Basis
Cogent Biosciences, Inc. (COGT) had Available-for-sale Securities, Amortized Cost Basis of $0 as of 2019-09-30, per its 10-Q filed 2019-11-12.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2019-11-12
- 2019-09-30: Available-for-sale Securities, Amortized Cost Basis $0.00.
- 2019-06-30: Available-for-sale Securities, Amortized Cost Basis $0.00.
- 2019-03-31: Available-for-sale Securities, Amortized Cost Basis $7.99M.
- 2018-12-31: Available-for-sale Securities, Amortized Cost Basis $22.93M.
| Period end | Available-for-sale Securities, Amortized Cost Basis |
|---|---|
| 2019-09-30 | $0.00 10-Q · filed 2019-11-12 |
| 2019-06-30 | $0.00 10-Q · filed 2019-08-12 |
| 2019-03-31 | $7.99M 10-Q · filed 2019-05-13 |
| 2018-12-31 | $22.93M 10-Q · filed 2019-11-12 |
| 2018-09-30 | $37.85M 10-Q · filed 2018-11-13 |
| 2018-06-30 | $47.73M 10-Q · filed 2018-08-13 |
| 2018-03-31 | $6.70M 10-Q · filed 2018-05-14 |
| 2017-12-31 | $12.71M 10-K · filed 2019-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |